Shareholders support Management proposals at SYGNIS Pharma's AGM with overwhelming majority
(Thomson Reuters ONE) -
SYGNIS Pharma /
Shareholders support Management proposals at SYGNIS Pharma's AGM with
overwhelming majority
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Madrid/Heidelberg, 30 August 2013 - At the Annual General Meeting (AGM) of
SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) held on
28 August 2013 shareholders representing about 94 percent of the capital
approved all proposals of the Management with an overwhelming majority. Main
decisions were related to the discharge of the members of the Supervisory and
the Management Board for the past Fiscal Year, the election of new members of
the Supervisory Board, the change of the trade name of the Company (new trade
name will be: SYGNIS AG), as well as the creation of new authorised capital.
Dr. Wolf-Dieter Starp and Mr. Gonzalo Rodriguez-Fraile Díaz have left the
Supervisory Board. Dr. Cristina Garmendia Mendizábal, chairwoman of the
Supervisory Board thanked Dr. Starp and Mr. Gonzalo Rodriguez-Fraile Díaz for
their work and efforts for SYGNIS Pharma AG. She welcomed Dr. Franz Wilhelm Hopp
and Mr. Werner-Friedrich Knuth Schäfer as new members of the Supervisory Board.
At the AGM Pilar de la Huerta, CEO/CFO, confirmed expectations that Qiagen will
launch first products with QualiPhi(®) by autumn 2013.
For further information please contact:
SYGNIS Pharma AG
Pilar de la Huerta
CEO/CFO
Tel: +34-918063089
Email: pdelahuerta(at)sygnis.es
About SYGNIS Pharma AG: www.sygnis.de
After the merger in 2012 between X-Pol Biotech, specialising in DNA
amplification and sequencing, and SYGNIS Pharma AG, listed in the German Stock
Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new
mission is to develop and distribute technologies and products from X-Pol, which
has a commercial product in the DNA amplification segment, QualiPhi(®) and is
currently developing other products in the field of Next Generation Sequencing.
### Disclaimer
Some statements included in this press release, relating neither to proven
financial results nor other historical data, should be viewed as forward-
looking, i.e. not definite. Such statements are mainly predictions of future
results, trends, plans or goals. These statements should not be considered to be
total guarantees since given their very nature they are subject to known and
unknown risks and imponderability and can be affected by other factors as a
consequence of which the actual results, plans and goals of SYGNIS Pharma AG may
deviate greatly from the established conclusions or implied predictions
contained in such statements. SYGNIS does not undertake to publicly update or
revise these statements in the light of new information or future results or for
any other reason. ###
Press Release (PDF):
http://hugin.info/150277/R/1726151/575896.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: SYGNIS Pharma via Thomson Reuters ONE
[HUG#1726151]
Unternehmensinformation / Kurzprofil:
Datum: 30.08.2013 - 12:04 Uhr
Sprache: Deutsch
News-ID 292500
Anzahl Zeichen: 3975
contact information:
Town:
Heidelberg
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 217 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Shareholders support Management proposals at SYGNIS Pharma's AGM with overwhelming majority"
steht unter der journalistisch-redaktionellen Verantwortung von
SYGNIS Pharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
